© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation
aDepartment of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan
bGenome Information Research Center, Osaka University, Suita, Japan
cDepartment of Medical Information Science, Osaka University Graduate School of Medicine, Suita, Japan
kazuhiro{at}medone.med.osaka-u.ac.jp
* Corresponding author. Tel.: +81-6-6879-6612; fax: +81-6-6879-6613.
Objective: Remodeling of extracellular matrix (ECM) is considered to contribute to progression of left ventricular (LV) remodeling and matrix metalloproteinases (MMPs) play crucial roles in regulation of ECM. Activation of MMPs is observed in systolic heart failure (SHF) and is suggested to be responsible for LV dilatation in SHF. Diastolic heart failure (DHF) that is not associated with LV dilatation is also accompanied with collagen accumulation; however, differences in ECM regulatory system, especially activation of MMPs, between SHF and DHF remain to be clarified. This study was conducted to clarify whether MMPs are activated even in DHF, and if so, to characterize the difference in activation of MMPs between SHF and DHF for identification of a target for the prevention of LV remodeling in SHF. Methods: To exclude effects of differences in underling cardiovascular diseases and genetic background on the comparison between DHF and SHF, we used Dahl salt-sensitive rats fed on high salt diet starting at 7 weeks of age as DHF model and at 8 weeks as SHF model, both of which our laboratory recently developed. Results: LV fibrosis progressed in the DHF and SHF model rats. MMP-2 was activated to the same degree in both rats. Activation of MMP-9 was enhanced in the DHF model rats, but the activity was more enhanced in the SHF rats. Film in situ zymography showed that enhanced gelatinolytic activity appeared only in the mid layer of the LV wall in the DHF rats and throughout the wall in the SHF rats. The distribution of gelatinolytic activity was consistent with that of expression of MMP-9 as assessed in immunohistochemical study. Conclusions: MMP-9 rather than MMP-2 may be involved in LV dilatation in SHF and be a specific target for the prevention of LV remodeling.
KEYWORDS Extracellular matrix; Fibrosis; Heart failure; Hypertension; Remodeling
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Sam, T.-A. S. Duhaney, K. Sato, R. M. Wilson, K. Ohashi, S. Sono-Romanelli, A. Higuchi, D. S. De Silva, F. Qin, K. Walsh, et al. Adiponectin Deficiency, Diastolic Dysfunction, and Diastolic Heart Failure Endocrinology, January 1, 2010; 151(1): 322 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Dhalla, H. K. Saini-Chohan, D. Rodriguez-Leyva, V. Elimban, M. R. Dent, and P. S. Tappia Subcellular remodelling may induce cardiac dysfunction in congestive heart failure Cardiovasc Res, February 15, 2009; 81(3): 429 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Westermann, A. Riad, O. Lettau, A. Roks, K. Savvatis, P. M. Becher, F. Escher, A.H. Jan Danser, H.-P. Schultheiss, and C. Tschope Renin Inhibition Improves Cardiac Function and Remodeling After Myocardial Infarction Independent of Blood Pressure Hypertension, December 1, 2008; 52(6): 1068 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H.M. Hessel, G. B. Bleeker, J. J. Bax, M. M. Henneman, B. den Adel, M. Klok, M.J. Schalij, D. E. Atsma, and A. van der Laarse Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels Eur J Heart Fail, October 1, 2007; 9(10): 1058 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Graham and A. W. Trafford Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1364 - H1372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. De Keulenaer and D. L. Brutsaert Systolic and diastolic heart failure: Different phenotypes of the same disease? Eur J Heart Fail, February 1, 2007; 9(2): 136 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Herrmann, O. Taban-Shomal, U. Hubner, M. Bohm, and W. Herrmann A review of homocysteine and heart failure Eur J Heart Fail, October 1, 2006; 8(6): 571 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nemori, M. Yamamoto, F. Kataoka, G. Hashimoto, H. Arakatsu, T. Shiomi, and Y. Okada Development of In Situ Zymography to Localize Active Matrix Metalloproteinase-7 (Matrilysin-1) J. Histochem. Cytochem., October 1, 2005; 53(10): 1227 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yoshida, K. Yamamoto, T. Mano, Y. Sakata, M. Nishio, T. Ohtani, M. Hori, T. Miwa, and T. Masuyama Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats Cardiovasc Res, October 1, 2005; 68(1): 118 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Rude, T.-A. S. Duhaney, G. M. Kuster, S. Judge, J. Heo, W. S. Colucci, D. A. Siwik, and F. Sam Aldosterone Stimulates Matrix Metalloproteinases and Reactive Oxygen Species in Adult Rat Ventricular Cardiomyocytes Hypertension, September 1, 2005; 46(3): 555 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Schiotz Thorud, A. Stranda, J.-A. Birkeland, P. K. Lunde, I. Sjaastad, S. O. Kolset, O. M. Sejersted, and P. O. Iversen Enhanced matrix metalloproteinase activity in skeletal muscles of rats with congestive heart failure Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R389 - R394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fraccarollo, P. Galuppo, I. Schmidt, G. Ertl, and J. Bauersachs Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction Cardiovasc Res, July 1, 2005; 67(1): 97 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sarin, R. D Gaffin, G. A Meininger, and M. Muthuchamy Arginine-glycine-aspartic acid (RGD)-containing peptides inhibit the force production of mouse papillary muscle bundles via {alpha}5{beta}1 integrin J. Physiol., April 15, 2005; 564(2): 603 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsuruda, J. Kato, K. Hatakeyama, H. Masuyama, Y.-N. Cao, T. Imamura, K. Kitamura, Y. Asada, and T. Eto Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats Cardiovasc Res, March 1, 2005; 65(4): 921 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Kuster, E. Kotlyar, M. K. Rude, D. A. Siwik, R. Liao, W. S. Colucci, and F. Sam Mineralocorticoid Receptor Inhibition Ameliorates the Transition to Myocardial Failure and Decreases Oxidative Stress and Inflammation in Mice With Chronic Pressure Overload Circulation, February 1, 2005; 111(4): 420 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heymans, F. Lupu, S. Terclavers, B. Vanwetswinkel, J.-M. Herbert, A. Baker, D. Collen, P. Carmeliet, and L. Moons Loss or Inhibition of uPA or MMP-9 Attenuates LV Remodeling and Dysfunction after Acute Pressure Overload in Mice Am. J. Pathol., January 1, 2005; 166(1): 15 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sundstrom, J. C. Evans, E. J. Benjamin, D. Levy, M. G. Larson, D. B. Sawyer, D. A. Siwik, W. S. Colucci, P. Sutherland, P. W.F. Wilson, et al. Relations of Plasma Matrix Metalloproteinase-9 to Clinical Cardiovascular Risk Factors and Echocardiographic Left Ventricular Measures: The Framingham Heart Study Circulation, June 15, 2004; 109(23): 2850 - 2856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sakata, K. Yamamoto, T. Mano, N. Nishikawa, J. Yoshida, M. Hori, T. Miwa, and T. Masuyama Activation of Matrix Metalloproteinases Precedes Left Ventricular Remodeling in Hypertensive Heart Failure Rats: Its Inhibition as a Primary Effect of Angiotensin-Converting Enzyme Inhibitor Circulation, May 4, 2004; 109(17): 2143 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yoshida, K. Yamamoto, T. Mano, Y. Sakata, N. Nishikawa, M. Nishio, T. Ohtani, T. Miwa, M. Hori, and T. Masuyama AT1 Receptor Blocker Added to ACE Inhibitor Provides Benefits at Advanced Stage of Hypertensive Diastolic Heart Failure Hypertension, March 1, 2004; 43(3): 686 - 691. [Abstract] [Full Text] [PDF]
|
|